// App-Quantinova.ai

LB-OR02-6 : Empagliflozin Reduces Blood Pressure in Patients with Type 2 Diabetes and Hypertension: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial (EMPA-REG BPTM)

Researchers

Presenter

  • Ilkka Tikkanen

Principal Investigators

  • Kirsi Narko

  • Cordula Zeller

  • Alexandra Green

  • Afshin Salsali

  • Uli C Broedl

  • Hans-Juergen Woerle

Medical Centers

  • inVentiv Health Clinical, Maidenhead, United Kingdom

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

Locations

  • Finland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Hypertension

  • Diabetes

Biomarkers

  • GC Vitamin D Binding Protein

  • Hemoglobin A1c

  • Sex hormone binding globulin

  • Body mass index

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved